ClinicalTrials.gg
RecruitingNCT07324837FRIDA-CTUpdated Nov 12, 2026

Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

A Phase 3 interventional study of non-immunogenic staphylokinase and Placebo in Ischemic Stroke, Acute, sponsored by Supergene, LLC. Recruiting at 17 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Supergene, LLC · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 12, 2026Site recruiting status changedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.

Started
2026
with 3 others
Phase 3
3 of 17
2 open now
Primary completion
2028-11
later than 9 of 12 live
Registered
12th of 17
by date
Lead sponsor
2 of 17
Supergene, LLC

Among the 17 studies in Ischemic Stroke with a site in Russia, this one is one of 4 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 9 of the 12 other live ones, and was the 12th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ischemic Stroke with a site in Russia, or all of them as a file.
02

Study summary

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.

Read the detailed description

The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.

In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.

A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.

Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.

In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume \<70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.

03

Conditions studied

  • Ischemic Stroke, Acute

Browse trials for

Keywords

  • Ischemic Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women aged 18 years and over;
  2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  3. Pre-stroke modified Rankin scale (mRS) score≤1;
  4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
  5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume \<70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
  6. Alberta Stroke Program Early CT score (ASPECTS) > 6;
  7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
  8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
  9. Written from patients or their legally authorized representatives.

Exclusion criteria

Exclusion Criteria:

  1. Acute ischemic stroke within 4,5 h after symptom onset;
  2. Intended to proceed to endovascular treatment;
  3. Known to the non-immunogenic staphylokinase;
  4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
  5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
  6. Blood glucose \<2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
  7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
  8. Subarachnoid hemorrhage;
  9. Major bleeding currently or within the past 6 months;
  10. Surgery on the brain or spinal cord in the last 2 months;
  11. Punctures of non-compressible arteries and veins in the last 7 days;
  12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
  13. count below 100,000/mm3;
  14. Previous stroke or severe traumatic brain injury within 3 months;
  15. Unable to perform CT or MRI;
  16. History of hemorrhagic stroke or stroke of unspecified genesis;
  17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
  18. Concomitant use of indirect oral anticoagulants (warfarin) with > 1.7;
  19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
  20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
  21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
  22. Acute pancreatitis;
  23. Bacterial endocarditis, pericarditis;
  24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
  25. Cancer with an increased risk of bleeding;
  26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
  27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
  28. Hemorrhagic diathesis, including renal and hepatic failure;
  29. Data on bleeding or acute trauma (fracture) at the time of examination;
  30. Pregnant women, nursing mothers, or reluctant to use effective measures during the period of trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,050 participants (estimated)

Study arms

  • Experimental
    Non-immunogenic staphylokinase

    The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

    Drug: non-immunogenic staphylokinase

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugauR protein, Staphylococcus aureusStudies of auR protein, Staphylococcus aureusauR protein, Staphylococcus aureus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

    Also known as: Fortelyzin®

  • DrugPlacebo

    Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization

06

What researchers measure

Primary outcomes

  1. Excellent functional outcome

    The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days

    Time frame: 90 days

Secondary outcomes

  1. Ordinal distribution of mRS

    Ordinal distribution of mRS at 90 days

    Time frame: 90 days

  2. Functional independence outcome

    The number of patients with functional independence defined by an mRS score 0-2 point at 90 days

    Time frame: 90 days

  3. NIHSS change from baseline

    NIHSS median change from baseline on discharge

    Time frame: 7-14 days

  4. The rate of improvement on reperfusion

    The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization.

    Time frame: 24 hours

  5. All-cause mortality

    Rate of all-cause mortality within 90 days

    Time frame: 90 days

  6. Poor functional outcome

    The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days

    Time frame: 90 days

Other outcomes

  1. Hemorrhagic transformation

    Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours

    Time frame: 24 hours

  2. Symptomatic intracranial hemorrhage

    Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria \[ECASSIII\] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study \[SITS-MOST\]) within 24 hours

    Time frame: 24 hours

  3. Major bleeding

    Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5)

    Time frame: 90 days

  4. Serious adverse events (SAEs)

    Rate of serious adverse events (SAEs) within 90 days

    Time frame: 90 days

07

Study locations

14 of 17 sites recruiting
  • Ryazan Regional Clinical Hospital
    Ryazan, Ryazan Oblast 390039, Russia
    Not yet recruiting
    • Sergei B. Aksentyev, PhD · Contactaksentievs@mail.ru
    • Sergei B. Aksentyev, PhD · Principal investigator
  • Chelyabinsk Regional Clinical Hospital No. 3
    Chelyabinsk, Russia
    Recruiting
  • Irkutsk Regional Clinical Hospital
    Irkutsk, 664079, Russia
    Recruiting
    • Ivan V. Korobeynikov, PhD · ContactIrk.ivan@gmail.com
    • Ivan V. Korobeynikov, PhD · Principal investigator
  • Interregional Clinical and Diagnostic Center
    Kazan', 420101, Russia
    Recruiting
    • Dina R. Khasanova, MD, Prof · Contactdhasanova@mail.ru
    • Dina R. Khasanova, MD, Prof · Principal investigator
  • S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
    Krasnodar, 350086, Russia
    Recruiting
    • Ludmila V. Timchenko, MD, prof · Contacttlv2908@yandex.ru
    • Ludmila V. Timchenko, MD, prof · Principal investigator
  • Krasnogorsk Clinical Hospital
    Krasnogorsk, 143408, Russia
    Recruiting
    • Svetlana V. Alexandrova · Contactclairalex@mail.ru · (498) 602-03-73
    • Svetlana V. Alexandrova · Principal investigator
  • Moscow Multidisciplinary Clinical Center "Kommunarka"
    Moscow, 108814, Russia
    Recruiting
    • Denis N. Protsenko, PhD · ContactProtsenkoDN@zdrav.mos.ru · (495) 744-07-03
    • Denis N. Protsenko, PhD · Principal investigator
  • N.I. Pirogov Russian National Research Medical University
    Moscow, 117997, Russia
    Recruiting
    • Larisa L. Korsunskaya, MD, Prof · Contactneurocrimea@mail.ru
    • Larisa L. Korsunskaya, MD, Prof · Principal investigator
  • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
    Nizhny Novgorod, 603126, Russia
    Not yet recruiting
    • Valentina N. Nesterova, PhD · Contactnesterova-78@mail.ru · (831) 438-95-38
    • Valentina N. Nesterova, PhD · Principal investigator
  • V.I. Voynov Orenburg Regional Clinical Hospital
    Orenburg, Russia
    Recruiting
    • Alexandr N. Chirkov, PhD · Contactlog82@mail.ru
    • Alexandr N. Chirkov, PhD · Principal investigator
  • St. Petersburg Hospital for War Veterans
    Saint Petersburg, 193079, Russia
    Recruiting
    • Maria A. Privalova, PhD · Contactprivamariya@yandex.ru · (812) 670-94-44
    • Maria A. Privalova, PhD · Principal investigator
  • Leningradskaya Regional Clinical Hospital
    Saint Petersburg, 194291, Russia
    Recruiting
    • Natalya V. Zhukovskaya, MD, prof · Contactnataly.lokb@mail.ru
    • Natalya V. Zhukovskaya, MD, prof · Principal investigator
  • Solnechnogorsk District Hospital
    Solnechnogorsk, 141508, Russia
    Not yet recruiting
    • Anton G. Koledinsky, MD, PhD · Contactkoledant@mail.ru · (496) 264-14-56
    • Anton G. Koledinsky, MD, PhD · Principal investigator
  • Tver Regional Clinical Hospital
    Tver', 170036, Russia
    Recruiting
    • Ksenia V. Khoroshavina · Contactkseniarep@mail.ru · (482) 277-54-65
    • Ksenia V. Khoroshavina · Principal investigator
  • Ulyanovsk Regional Clinical Hospital
    Ulyanovsk, Russia
    Recruiting
    • Irina V. Greshnova, PhD · Contacttonuus@mail.ru
    • Irina V. Greshnova, PhD · Principal investigator
  • City Clinical Hospital of Emergency Medical Care No. 25
    Volgograd, 400138, Russia
    Recruiting
    • Eduard A. Ponomarev, MD, prof · Contactponomarev67@mail.ru
    • Eduard A. Ponomarev, MD, prof · Principal investigator
  • Sverdlovsk Regional Clinical Hospital No. 1
    Yekaterinburg, 620102, Russia
    Recruiting
    • Andrey M. Alasheev, MD, prof · Contactalasheev@live.ru
    • Andrey M. Alasheev, MD, prof · Principal investigator
08

References and documents

Publications

  • Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, Yarovaya EB, Semenov AM, Archakov AI, Markin SS; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021 Sep;20(9):721-728. doi: 10.1016/S1474-4422(21)00210-6. PubMed 34418399 ↗
  • Shamalov NA, Martynov MY, Yarovaya EB, Chefranova ZY, Kutsenko VA, Semenov AM, Ivanov SV, Semenov MP, Markin SS, Gusev EI; FORPI Study Group. Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study. Stroke. 2026 Feb;57(2):394-403. doi: 10.1161/STROKEAHA.125.051115. Epub 2025 Nov 26. PubMed 41293810 ↗

Individual participant data

Plan to share: Yes — The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: within 90 days after request

Access criteria: Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2028, 28 months after the start.

Of 167 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 8, 2026
StartActual
Jun 9, 2026
Primary completionEst.
Nov 1, 2028
CompletionEst.
Jan 1, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 6 sites removed. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Chelyabinsk Regional Clinical Hospital No. 3 · Chelyabinsk, RussiaNot yet recruiting→Recruiting
  • City Clinical Hospital of Emergency Medical Care No. 25 · Volgograd, RussiaNot yet recruiting→Recruiting
  • Interregional Clinical and Diagnostic Center · Kazan', RussiaNot yet recruiting→Recruiting
  • Krasnogorsk Clinical Hospital · Krasnogorsk, RussiaNot yet recruiting→Recruiting
  • Moscow Multidisciplinary Clinical Center "Kommunarka" · Moscow, RussiaNot yet recruiting→Recruiting
  • N.I. Pirogov Russian National Research Medical University · Moscow, RussiaNot yet recruiting→Recruiting
Show site
  • Solnechnogorsk District Hospital · Solnechnogorsk, Russia
Show 6 removed
  • Altai Regional Clinical Hospital · Barnaul, Russia
  • Kaluga Regional Clinical Hospital · Kaluga, Russia
  • F.I. Inozemtsev Moscow City Clinical Hospital · Moscow, Russia
  • L.A. Vorokhobov Moscow City Clinical Hospital No. 67 · Moscow, Russia
  • A.K. Yeramishantsev Moscow City Clinical Hospital · Moscow, Russia
  • Sergiev Posad District Hospital · Sergiyev Posad, Russia
across 2 updates, Oct 1, 2026 – Nov 12, 2026
Enrollment
990→1050
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added, 1 site removed. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Interregional Clinical and Diagnostic Center · Kazan', RussiaNot yet recruiting→Recruiting
    • Krasnogorsk Clinical Hospital · Krasnogorsk, RussiaNot yet recruiting→Recruiting
    • Moscow Multidisciplinary Clinical Center "Kommunarka" · Moscow, RussiaNot yet recruiting→Recruiting
    • N.I. Pirogov Russian National Research Medical University · Moscow, RussiaNot yet recruiting→Recruiting
    Show site
    • Solnechnogorsk District Hospital · Solnechnogorsk, Russia
    Show 1 removed
    • Sergiev Posad District Hospital · Sergiyev Posad, Russia
    Enrollment 990→1050
    + 1 other change: verification date
  2. Oct 1, 2026
    5 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Chelyabinsk Regional Clinical Hospital No. 3 · Chelyabinsk, RussiaNot yet recruiting→Recruiting
    • City Clinical Hospital of Emergency Medical Care No. 25 · Volgograd, RussiaNot yet recruiting→Recruiting
    Show 5 removed
    • Altai Regional Clinical Hospital · Barnaul, Russia
    • Kaluga Regional Clinical Hospital · Kaluga, Russia
    • F.I. Inozemtsev Moscow City Clinical Hospital · Moscow, Russia
    • L.A. Vorokhobov Moscow City Clinical Hospital No. 67 · Moscow, Russia
    • A.K. Yeramishantsev Moscow City Clinical Hospital · Moscow, Russia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07324837
Lead sponsor
Supergene, LLC
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Jun 9, 2026
Primary completion
Nov 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Nikolay A. Shamalov, MD, prof
Contact
shamalovn@gmail.com
(499) 936-99-37 ext. +7
Natalya A. Marskaya
Contact
marskayana@gmail.com
(499) 936-99-37 ext. +7
Nikolay A. Shamalov, MD, prof
principal investigator · Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
Sergey S. Markin, MD, prof
study director · LLC "SuperGene"

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion